Shionogi to buy US biopharma IntraBio for $2bn

Created at 5 Oct · 4:31 PM1 source↑ Market-relevant

IN SHORT

Japanese drugmaker Shionogi will acquire U.S.-based IntraBio for $2 billion, aiming to expand its rare disease drug business and bolster its sales network in the United States. The deal is expected to make treatments for rare diseases a key growth area for Shionogi.

Key Numbers

$2 billionacquisition price for IntraBio

Who's Involved

Shionogi

Japanese drugmaker acquiring IntraBio

IntraBio

U.S.-based biopharma company to be acquired by Shionogi

↳ Why This Matters

The deal allows Shionogi to expand its presence in the lucrative rare disease market and gain access to IntraBio's existing sales channels in the U.S., potentially accelerating its global growth strategy.

Key facts

Shionogi will acquire U.S.-based IntraBio for $2 billion.
The acquisition aims to expand Shionogi's rare disease drug business.
The deal is expected to enhance Shionogi's sales network in the U.S.

Japanese drugmaker Shionogi announced its intention to acquire U.S.-based biopharma company IntraBio for $2 billion. The move is part of Shionogi's strategy to establish treatments for rare diseases as a core pillar of its future growth. The acquisition is also expected to significantly expand Shionogi's sales network within the United States.

Shionogi to buy US biopharma IntraBio for $2bn

Key Numbers

Who's Involved

↳ Why This Matters

Key facts

How It Developed

Shionogi to buy US biopharma IntraBio for $2bn

Key Numbers

Who's Involved

↳ Why This Matters

Key facts

How It Developed

Sources

Related Stories